CABIO Biotech Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
407
- Stock Symbol
-
688089
- Investments
-
3
- Share Price
-
$2.55
- (As of Friday Closing)
CABIO Biotech General Information
Description
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Contact Information
Website
www.cabio.cn
Formerly Known As
Cabio Bioengineering (Wuhan) Co. Ltd., CABIO-Bioengineering, Cabio Bioengineering Co. Ltd, Cabio Bioengineering, Kerry Symbio Bioengineering, Cabio Bioengineering (Wuhan)
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Food Products
Other Industries
Biotechnology
Stock Exchange
SHG
Primary Office
- No. 999, Gaoxin Avenue, East Lake New Technology Development Zone
- Wuhan, Hubei 430073
- China
+86 027 0000 0000
CABIO Biotech Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.55 | $2.60 | $2.38 - $5.76 | $437M | 168M | 1.63M | $0.01 |
CABIO Biotech Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 400,485 | 706,610 | 1,049,070 | 605,816 |
| Revenue | 68,760 | 64,358 | 54,376 | 46,820 |
| EBITDA | 7,104 | 14,860 | 26,233 | 26,032 |
| Net Income | 6,652 | 9,559 | 19,913 | 18,902 |
| Total Assets | 213,229 | 233,477 | 227,246 | 211,657 |
| Total Debt | 1,612 | 4,790 | 379 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
CABIO Biotech Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CABIO Biotech Patents
CABIO Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019299299-A1 | Method for lowering iodine value of glyceride | Active | 04-Jul-2018 | 00000000 | |
| AU-2019299299-B2 | Method for lowering iodine value of glyceride | Active | 04-Jul-2018 | 00000000 | 0 |
CABIO Biotech Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Dewei Yi | Chairman & President | ||
| Huabiao Wang | Director, Finance & Board Member |
CABIO Biotech Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000 00 | CABIO Biotech | Chairman & President | 000 0000 |
| 0000000 0000 | CABIO Biotech | Director, Finance & Board Member | 000 0000 |
CABIO Biotech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
CABIO Biotech Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CABIO Biotech Investments (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| JUSHU | 13-Jan-2023 | 00000 0000 | 00.000 | Biotechnology | |
| PuDuZhongHe | 08-Jan-2023 | 00000 0000 | Diagnostic Equipment | ||
| MIT Technology Review China | 29-Jun-2022 | Early Stage VC | Publishing |